Drug intelligence / Profile preview

acetylsalicylic acid + duloxetine

Development stage
Preclinical
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of two pharmaceutical agents, acetylsalicylic acid (commonly known as aspirin) and duloxetine. Acetylsalicylic acid is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase-1 and -2 (COX-1/COX-2), leading to decreased synthesis of prostaglandins and thromboxanes, which results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that increases the levels of these neurotransmitters in the central nervous system by inhibiting their reuptake at synaptic clefts. This dual mechanism provides antidepressant effects as well as pain modulation. The combination may be considered for patients with comorbid pain conditions requiring both an NSAID for inflammation/pain relief and an SNRI for neuropathic pain or mood disorders; however, caution is warranted due to increased risk of gastrointestinal bleeding when combining SNRIs with NSAIDs like aspirin[5][6]. There are no widely recognized brand names or fixed-dose products containing this exact combination.

Other names
aspirin + duloxetine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on acetylsalicylic acid + duloxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetylsalicylic acid + duloxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call